Paradoxically Greater Persistence of HIV RNA-Positive Cells in Lymphoid Tissue When ART Is Initiated in the Earliest Stage of Infection.
HIV reservoir
acute HIV infection
antiretroviral therapy
in situ hybridization
lymphoid tissues
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
15 06 2022
15 06 2022
Historique:
received:
04
10
2021
accepted:
09
03
2022
pubmed:
12
3
2022
medline:
18
6
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
Starting antiretroviral therapy (ART) in Fiebig 1 acute HIV infection limits the size of viral reservoirs in lymphoid tissues, but does not impact time to virus rebound during a treatment interruption. To better understand why the reduced reservoir size did not increase the time to rebound we measured the frequency and location of HIV RNA+ cells in lymph nodes from participants in the RV254 acute infection cohort. HIV RNA+ cells were detected more frequently and in greater numbers when ART was initiated in Fiebig 1 compared to later Fiebig stages and were localized to the T-cell zone compared to the B-cell follicle with treatment in later Fiebig stages. Variability of virus production in people treated during acute infection suggests that the balance between virus-producing cells and the immune response to clear infected cells rapidly evolves during the earliest stages of infection. Clinical Trials Registration: NCT02919306.
Identifiants
pubmed: 35275599
pii: 6547240
doi: 10.1093/infdis/jiac089
pmc: PMC9200151
doi:
Substances chimiques
Anti-Retroviral Agents
0
RNA, Viral
0
Banques de données
ClinicalTrials.gov
['NCT02919306']
Types de publication
Clinical Study
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2167-2175Subventions
Organisme : National Institute of Allergy and Infectious Diseases
ID : R01A125127
Organisme : NIH HHS
ID : AAI20052001
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Retrovirology. 2013 May 29;10:56
pubmed: 23718762
Science. 1997 May 9;276(5314):960-4
pubmed: 9139661
Lancet HIV. 2019 Apr;6(4):e259-e268
pubmed: 30885693
Clin Vaccine Immunol. 2006 May;13(5):556-60
pubmed: 16682476
AIDS. 2005 Dec 2;19(18):2169-71
pubmed: 16284469
Antimicrob Agents Chemother. 2021 May 18;65(6):
pubmed: 33782003
Nat Med. 2018 Jul;24(7):923-926
pubmed: 29892063
AIDS. 2022 Jun 1;36(7):985-990
pubmed: 35184069
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1126-34
pubmed: 25713386
Sci Transl Med. 2020 Mar 4;12(533):
pubmed: 32132218
J Infect Dis. 1997 Nov;176(5):1198-208
pubmed: 9359719
J Virol. 2016 Nov 14;90(23):10436-10445
pubmed: 27630237
Nature. 1993 Mar 25;362(6418):359-62
pubmed: 8096068
Pathog Immun. 2016 Spring;1(1):68-106
pubmed: 27430032
AIDS. 2015 Apr 24;29(7):793-800
pubmed: 25985402
J Infect Dis. 2001 Feb 15;183(4):555-62
pubmed: 11170980
Science. 1999 Nov 12;286(5443):1353-7
pubmed: 10558989
Annu Rev Immunol. 1999;17:625-56
pubmed: 10358770
Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):357-61
pubmed: 8419941
Sci Transl Med. 2019 May 22;11(493):
pubmed: 31118290
Nat Med. 2017 Nov;23(11):1271-1276
pubmed: 28967921
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12
pubmed: 24469825
J Infect Dis. 2005 May 1;191(9):1410-8
pubmed: 15809898
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202771
EBioMedicine. 2016 Sep;11:68-72
pubmed: 27460436
Blood. 2012 Oct 25;120(17):3466-77
pubmed: 22955926
J Clin Invest. 2002 Oct;110(8):1133-9
pubmed: 12393849
J Immunol. 2007 Jun 1;178(11):6975-83
pubmed: 17513747
Blood Adv. 2018 Jan 23;2(2):76-84
pubmed: 29365313
J Infect Dis. 2000 Jan;181(1):354-7
pubmed: 10608788